Abstract
Background: Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular impairment, increasing the rates of atherosclerotic and non-atherosclerotic events. Additionally, adverse kidney events are directly linked with T2DM and cardiovascular diseases. In this context, the sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated both cardioprotective and renoprotective effects in patients with or without T2DM. Therefore, the present meta-analysis aims to evaluate cardiovascular outcomes involving SGLT2i as monotherapy or other add-on antidiabetic agents (ADA) in patients with or [...]
Highlights
A search was conducted on the Google Scholar, Scielo, and PubMed databases using the keywords: “sodium-glucose cotransporter 2 inhibitors”, “heart failure”, “hospitalization", and "cardiovascular outcomes"
Seven of the nine selected trials have analyzed the rate of major adverse cardiovascular events (MACE)
It is essential to highlight that the sodium-glucose cotransporter 2 inhibitors (SGLT2i) monotherapy studies exerted the most noteworthy outcomes
Summary
Around 63 million people present heart failure worldwide,[1,2] and this condition costs billion dollars to health care,[3] This syndrome is associated with high morbidity and mortality rates, since it has a poor prognosis due to the difficulty in recognizing high-risk and pre-clinical stage patients linked to the problem of an appropriate early treatment.[1,4,5] Despite many designed trials, no adequate pharmacological treatment was found for heart failure with preserved ejection fraction (EF>50%)[6,7,8], which most likely represents 65% of heart failure in 2020.1,6Among the remarkable consequences of heart failure is the cardiorenal syndrome.[9]. SGLT2i cardioprotective effects and low cardiac output, leading to renal inflammation; sympathetic overstimulation; elevated sodium and consequent fluid retention; as well as atherosclerosis, anemia, and the of uremic toxins.[1,9] Altogether, these pathological mechanisms enhance the risk of cardiovascular adverse events, worsening heart failure.[1]. Adverse kidney events are directly linked with T2DM and cardiovascular diseases In this context, the sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated both cardioprotective and renoprotective effects in patients with or without T2DM. The present meta-analysis aims to evaluate cardiovascular outcomes involving SGLT2i as monotherapy or other add-on antidiabetic agents (ADA) in patients with or without T2DM. Objetive: The present meta-analysis aims to evaluate cardiovascular outcomes involving SGLT2i as monotherapy or add-on other ADA in patients with or without T2DM.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
